↓ Skip to main content

An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol

Overview of attention for article published in BMC Neurology, May 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
244 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol
Published in
BMC Neurology, May 2016
DOI 10.1186/s12883-016-0593-4
Pubmed ID
Authors

Peter Joseph Jongen, Marco Heerings, Rob Ruimschotel, Astrid Hussaarts, Silvia Evers, Lotte Duyverman, Joyce Valkenburg-Vissers, Job Cornelissen, Michel Bos, Maarten van Droffelaar, Wim A. Lemmens, Rogier Donders, Anneke van der Zande, Leo H. Visser

Abstract

In people with multiple sclerosis (MS) disabilities and limitations may negatively affect self-efficacy. Lowered self-efficacy has been associated with decreases in health-related quality of life, physical activity and cognitive performance. In an explorative observational study we found that a 3-day intensive social cognitive program (Can Do Treatment [CDT]) with the participation of support partners was followed by substantial increases in self-efficacy control and health-related quality of life 6 months after treatment in those people with MS who had relapsing remitting disease and low disability. CDT is a sociologically oriented approach, its goal is to uncover and promote existing capabilities, and the notion "stressor" is the central concept. CDT's components are plenary group sessions, small group sessions, consultations, a theatre evening, and start of the day with a joint activity. The small group sessions form the actual training. Depending on their individual goals the participants join the training groups 'Body', 'Feeling' or 'Life', to work out their aims and to reduce their stressors. The multidisciplinary team includes a psychiatrist, psychiatric nurse, neurologist, specialized MS nurse, physiotherapist, dance therapist, and a person with MS. To evaluate the (cost)effectiveness of CDT in persons with relapsing remitting MS and low disability we perform a single-centre, randomized controlled trial in 140 patients, with or without support partners. The primary outcome is self-efficacy control. The secondary outcomes are self-efficacy function, health-related quality of life, autonomy and participation, anxiety, depression, cost effectiveness and cost utility. The tertiary outcome is care-related strain to support partners. Outcomes are assessed at baseline and at 1, 3 and 6 months after CDT. This randomized controlled trial will adequately evaluate the clinical and cost effectiveness of a 3-day intensive social cognitive program in people with relapsing remitting MS and low disability, with self-efficacy control as primary outcome. Application number: 22444.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 244 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 244 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 35 14%
Student > Ph. D. Student 29 12%
Researcher 26 11%
Student > Doctoral Student 21 9%
Student > Bachelor 21 9%
Other 42 17%
Unknown 70 29%
Readers by discipline Count As %
Psychology 47 19%
Medicine and Dentistry 37 15%
Nursing and Health Professions 30 12%
Social Sciences 10 4%
Neuroscience 8 3%
Other 31 13%
Unknown 81 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2016.
All research outputs
#15,695,859
of 23,323,574 outputs
Outputs from BMC Neurology
#1,512
of 2,490 outputs
Outputs of similar age
#212,973
of 339,806 outputs
Outputs of similar age from BMC Neurology
#31
of 41 outputs
Altmetric has tracked 23,323,574 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,490 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,806 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.